BRIEF—Celgene files in EU and USA for ozanimod

Celgene has filed for the investigational immunotherapy ozanimod, to treat relapsing forms of multiple sclerosis (RMS) in the USA, and relapsing-remitting forms of the disease (RRMS) in Europe.

A decision in the USA is expected by March 25, 2020, and in Europe in the first half of 2020. Both applications are based primarily on data from the Phase III SUNBEAM and RADIANCE trials.

Chief medical officer Jay Backstrom said he believes ozanimod has the potential to be “an important option early in the treatment of relapsing forms of MS and a best-in-class S1P receptor modulator.”